DW Healthcare Partners (DWHP), a private equity firm focused on healthcare, has announced the sale of dermoscopy tools developer and manufacturer DermLite to FotoFinder Systems.
The financial terms of the deal were not disclosed.
DermLite, which is based in California,l is a portfolio company of DW Healthcare Partners’ Founders Fund.
It develops handheld dermoscopy solutions for use by dermatologists and other healthcare professionals. These solutions include dermatoscopes and phone adapters that use LED lights and magnification lenses to help the trained eye identify skin cancer and other skin diseases.
DermLite chief product officer Thorsten Trotzenberg said: “We would like to thank the team at DWHP for their support over the last three years.
“They have been excellent partners and have made significant contributions to the continued growth and success at DermLite.”
FotoFinder said that the acquisition will enable it to combine DermLite’s expertise in dermatoscope technology with the company’s advanced imaging systems.
The combined group is anticipated to provide a wide range of goods and services for cutting-edge dermatological research and diagnostics.
Customers will have access to an entire ecosystem of skin imaging tools, powered by state-of-the-art artificial intelligence (AI), ranging from handheld devices to whole body dermoscopy systems.
FotoFinder CEO Andreas Mayer said: “We’re excited to welcome DermLite to the FotoFinder family.
“This union represents a significant step in our mission to facilitate early detection and accurate diagnosis of skin cancer worldwide. Our shared vision is to provide our customers with everything they need for skin imaging under one roof.”
Based in Germany, FotoFinder is a portfolio company of EMZ Partners.
The company develops and distributes technologies like Automated Total Body Mapping, AI, and digital dermoscopy for early skin cancer detection.
With offices in Italy, the UK, and the US, and a global partner network, the company serves customers all over the world and is present in more than 90 countries.
